Access cutting-edge pku treatment through this clinical trial at a research site in Minneapolis. Study-provided care at no cost to qualified participants.
Access pku specialists in Minneapolis at no cost
This study follows strict safety protocols and ethical guidelines
All study-related pku treatment provided free
This is a Phase 1/2, open-label, multiple-center, dose escalation and cohort expansion study to evaluate the safety and efficacy of NGGT002 in adult subjects with classic Phenylketonuria (PKU). NGGT002 is an rAAV8 based vector carrying a functional copy of the human PAH gene. Participants will receive a single administration of NGGT002 and will be followed for safety and efficacy for 5 years.
Sponsor: NGGT INC.
Check if you qualify for this pku clinical trial in Minneapolis, MN
If you're searching for pku treatment options in Minneapolis, MN, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Minneapolis research site is actively enrolling participants for this clinical trial. You'll receive care from experienced pku specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.